AZD-7762 is primarily used in research settings as a checkpoint kinase inhibitor. It is studied for its potential to enhance the efficacy of DNA-damaging cancer therapies, such as chemotherapy and radiation. By inhibiting checkpoint kinases, AZD-7762 disrupts the cell cycle checkpoint mechanisms, preventing cancer cells from repairing DNA damage. This action can lead to increased cancer cell death when combined with treatments that induce DNA damage. Its application is largely focused on preclinical studies to explore its role in improving therapeutic outcomes in various cancer types.